Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.
Sponsor: Amgen
Terminated
Funding terminated
Listed as NCT03137537, this PHASE2 trial focuses on Autonomic Imbalance and Cancer Survivorship and remains terminated or withdrawn. Sponsored by Amgen, it has been updated 10 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Mar 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Sep 2021 — Mar 2022 [monthly]
Terminated PHASE2
Status: Suspended → Terminated
-
May 2021 — Sep 2021 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
▶ Show 5 earlier versions
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Oct 2018 — Jan 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Oct 2018 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
- Dana-Farber Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .